Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients' Population.

Autor: Al Nooryani A; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Aboushokka W; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., AlBaba B; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Kerfes J; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Abudaqa L; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Bhatia A; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Mansoor A; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Nageeb R; Al Qassimi Hospital, Sharjah 3500, United Arab Emirates., Aleksandric S; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Beleslin B; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2022 Jun 28; Vol. 11 (13). Date of Electronic Publication: 2022 Jun 28.
DOI: 10.3390/jcm11133726
Abstrakt: Background : The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance of Magmaris, drug-eluting bioresorbable metallic scaffold, in all-comers patients' population. Methods: We included in this prospective registry first 54 patients (54 ± 11 years; male 46) treated with Magmaris, with at least 30 months of follow-up. Diabetes mellitus and acute coronary syndrome were present in 33 (61%) and 30 (56%) of the patients, respectively. Patients were followed for device- and patient-oriented cardiac events during a median follow-up of 47 months (DOCE-cardiac death, target vessel myocardial infarction, and target lesion revascularization; POCE-all cause death, any myocardial infarction, any revascularization). Results: Event-free survivals for DOCE and POCE were 86.8% and 79.2%, respectively. The rate of DOCE was 7/54 (13%), including in total target vessel myocardial infarction in two patients (4%), target lesion revascularization in six patients (11%), and no cardiac deaths. The rate of POCE was 11/54 (21%), including in total any myocardial infarctions in 3 patients (6%), any revascularization in 11 patients (20%), and no deaths. Definite Magmaris thrombosis occurred in two patients (3.7%), and in-scaffold restenosis developed in five patients (9.3%). Variables associated with DOCE were implantation of ≥2 Magmaris BVS (HR: 5.4; 95%CI: 1.21-24.456; p = 0.027) and total length of Magmaris BVS ≥ 40 mm (HR: 6.4; 95%CI: 1.419-28.855; p = 0.016), whereas previous PCI was the only independent predictor of POCE (HR: 7.4; 95%CI: 2.216-24.613; p = 0.001). Conclusions: The results of the long-term clinical outcome following Magmaris implantation in patients with complex clinical and angiographic features were acceptable and promising. Patients with multi-BVS and longer multi-BVS in lesion implantation were associated with worse clinical outcome.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje